Related references
Note: Only part of the references are listed.Bisphosphonate-related osteonecrosis of the jaw: an overview
Salvatore L. Ruggiero
BISPHOSPHONATES AND OSTEONECROSIS OF THE JAW (2011)
Calcium Citrate and Vitamin D in the Treatment of Osteoporosis
Jose Manuel Quesada Gomez et al.
CLINICAL DRUG INVESTIGATION (2011)
Bisphosphonate Use and the Risk of Subtrochanteric or Femoral Shaft Fractures in Older Women
Laura Y. Park-Wyllie et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Osteoporosis: now and the future
Tilman D. Rachner et al.
LANCET (2011)
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009
S. Lee et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report
R. Rizzoli et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Adoption of Once-monthly Oral Bisphosphonates and the Impact on Adherence
Becky A. Briesacher et al.
AMERICAN JOURNAL OF MEDICINE (2010)
Long-Term Use of Bisphosphonates in Osteoporosis
Nelson B. Watts et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
From Randomized Controlled Trials to Observational Studies
Stuart L. Silverman
AMERICAN JOURNAL OF MEDICINE (2009)
RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction
J. R. Curtis et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Evaluating the Antifracture Efficacy of Bisphosphonates
Michael Pazianas et al.
REVIEWS ON RECENT CLINICAL TRIALS (2009)
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture
Suzanne M. Cadarette et al.
ANNALS OF INTERNAL MEDICINE (2008)
Medication compliance and persistence: Terminology and definitions
Joyce A. Cramer et al.
VALUE IN HEALTH (2008)
Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study
Paul D. Miller et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Osteoporosis medication profile preference: results from the PREFER-US study
Thomas W. Weiss et al.
HEALTH EXPECTATIONS (2007)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis
Pierre D. Delmas et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025
Russel Burge et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Compliance with osteoporosis drug therapy and risk of fracture
D. Weycker et al.
OSTEOPOROSIS INTERNATIONAL (2007)
A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis
Deborah T. Gold et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study
S. L. Silverman et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Patient adherence to osteoporosis medications - Problems, consequences and management strategies
Alexandra Papaioannou et al.
DRUGS & AGING (2007)
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial
Dennis M. Black et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency
Richard Keen et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate
Deborah T. Gold et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases
Ethel S. Siris et al.
MAYO CLINIC PROCEEDINGS (2006)
Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting
Timothy W. Downey et al.
SOUTHERN MEDICAL JOURNAL (2006)
Assessment of compliance with osteoporosis treatment and its consequences in a managed care population
KF Huybrechts et al.
BONE (2006)
An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study
Thomas W. Weiss et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Improving compliance and persistence with bisphosphonate therapy for osteoporosis
RD Emkey et al.
AMERICAN JOURNAL OF MEDICINE (2006)
Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO)
R Emkey et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Compliance with osteoporosis medications
DH Solomon et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis
D Felsenberg et al.
BONE (2005)
TREATMENT WITH ONCE-WEEKLY ALENDRONATE 70 MG COMPARED TO ONCE-WEEKLY RISEDRONATE 35 MG IN WOMEN WITH POSTMENOPAUSALE OSTEOPOROSIS: A RANDOMIZED DOUBLE-BLIND STUDY
Peter Pietschmann
JOURNAL FUR MINERALSTOFFWECHSEL (2005)
Efficacy of risedronate on clinical vertebral fractures within six months
C Roux et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis
JT Harrington et al.
CALCIFIED TISSUE INTERNATIONAL (2004)
The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled
JA Clowes et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial long-term extension
KE Ensrud et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
CH Chesnut et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Compliance with drug therapies for the treatment and prevention of osteoporosis
JS McCombs et al.
MATURITAS (2004)
Seven years of treatment with risedronate in women with postmenopausal osteoporosis
DD Mellström et al.
CALCIFIED TISSUE INTERNATIONAL (2004)
The impact of compliance with osteoporosis therapy on fracture rates in actual practice
JJ Caro et al.
OSTEOPOROSIS INTERNATIONAL (2004)
Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience
OH Sorensen et al.
BONE (2003)
A systematic review of the associations between dose regimens and medication compliance
AJ Claxton et al.
CLINICAL THERAPEUTICS (2001)
Effect of risedronate on the risk of hip fracture in elderly women
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women
FL Lanza et al.
GASTROENTEROLOGY (2000)
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
JY Reginster et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Share Paper
